Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest

Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest
Treatment with Xtandi (enzalutamide) does not seem to improve overall survival in men with non-metastatic castration-resistant prostate cancer (CRPC), according to the first interim analysis of a Phase 3 clinical trial. These findings were published in the study, “Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer,” in the New England Journal of Medicine. Men with non-metastatic CRPC and rapidly rising prostate-specific antigen (PSA) levels — a sign of rapid disease progression — are at a high risk of developing metastasis. Currently, only one recently approved treatment, Erleada (apalutamide), is available to these patients. Xtandi, an androgen receptor inhibitor, is an approved treatment for metastatic CRPC patients. It was shown to delay disease progression and prolong these patients’ overall survival. The Phase 3 PROSPER trial (NCT02003924) is evaluating whether adding Xtandi to standard androgen deprivation therapy (ADT) is better than ADT alone in patients with rising PSA levels. The randomized, double-blind, placebo-controlled trial enrolled 1,401 men with prostate cancer whose disease had progressed — based on r
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *